Glaucoma Detection Using Optical Coherence Tomography: Reviewing the Pitfalls of Comparison to Normative Data.

Autor:	Leshno A; Department of Ophthalmology, Bernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center.; School of Medicine, Tel-Aviv University, Tel-Aviv, Israel., De Moraes CG; Department of Ophthalmology, Bernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center., Tsamis E; Department of Psychology, Columbia University Schermerhorn Hall, New York, NY., La Bruna S; Department of Psychology, Columbia University Schermerhorn Hall, New York, NY., Cioffi GA; Department of Ophthalmology, Bernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center., Liebmann JM; Department of Ophthalmology, Bernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center., Hood DC; Department of Ophthalmology, Bernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center.; Department of Psychology, Columbia University Schermerhorn Hall, New York, NY.
Jazyk:	angličtina
Zdroj:	Journal of glaucoma [J Glaucoma] 2024 Feb 01; Vol. 33 (2), pp. 65-77. Date of Electronic Publication: 2023 Nov 24.
DOI:	10.1097/IJG.0000000000002337
Abstrakt:	Prcis: Optical coherence tomography is essential in managing glaucoma. This review describes various artifacts that originate from using a normative database to compare the individual's scans. This is a review paper regarding artifacts in optical coherence tomography imaging for glaucoma arising from using a normative database as a reference for healthy retinal nerve fiber layer and ganglion cell layer. Competing Interests: Disclosure: D.C.H.: Topcon, Inc. (F, R); Heidelberg Engineering (F, R); Novartis, Inc. (F, R). C.G.D.M.: Carl Zeiss Meditec, Inc. (C); Novartis (C); Heidelberg Engineering (R); Topcon (F); Galimedix (C); Perfuse Therapeutics (C); Ora Clinical, Inc. (E). J.M.L.: Novartis (R), Alcon (C), Allergan (C), Genentech (C), Thea (C), Carl Zeiss Meditech, (C). The remaining authors declare no conflict of interest. (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu